• Gene fusion; HGNC; 16063; MLLT10 + HGNC; 15514; PICALM; Name(s)=PICALM-MLLT10, CALM-AF10 (from parent cell line).
  
• Mutation; HGNC; 9588; PTEN; Simple; p.Gly129fs*51 (c.387_388insCGCC); Zygosity=Hemizygous (DepMap=ACH-002314).
  
• Mutation; HGNC; 9644; PTPN11; Simple; p.Gly60Arg (c.178G>C); ClinVar=VCV000372590; Zygosity=Heterozygous (DepMap=ACH-002314).
  
• Mutation; HGNC; 11998; TP53; Simple; c.559+1G>A (p.Val173Trpfs*59); ClinVar=VCV000428908; Zygosity=Homozygous; Note=Splice donor mutation (DepMap=ACH-002314).
  
• Mutation; HGNC; 12796; WT1; Simple; p.Arg301Ter (c.901C>T) (p.Arg352Ter, c.1054C>T) (p.Arg374Ter, c.1120C>T); ClinVar=VCV000449416; Zygosity=Heterozygous (DepMap=ACH-002314).
  

PubMed=8398907
Hass R., Hirano M., Kharbanda S., Rubin E.H., Meinhardt G., Kufe D.W.
Resistance to phorbol ester-induced differentiation of a U-937 myeloid leukemia cell variant with a signaling defect upstream to Raf-1 kinase.
Cell Growth Differ. 4:657-663(1993)

PubMed=7720732
Hass R., Meinhardt G., Hadam M.R., Bartels H.
Characterization of human TUR leukemia cells: continued cell cycle progression in the presence of phorbol ester is associated with resistance to apoptosis.
Eur. J. Cell Biol. 65:408-416(1994)

PubMed=20164919; DOI=10.1038/nature08768; PMCID=PMC3145113
Bignell G.R., Greenman C.D., Davies H.R., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.
Signatures of mutation and selection in the cancer genome.
Nature 463:893-898(2010)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017; PMCID=PMC4967469
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X., Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747; PMCID=PMC6445675
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Cancer Res. 79:1263-1273(2019)

PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010; PMCID=PMC9387775
Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N., Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J., Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L., Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S., Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B., Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.
Pan-cancer proteomic map of 949 human cell lines.
Cancer Cell 40:835-849.e8(2022)